Propofol maintenance for ventilated patient
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Here is a comprehensive summary of propofol maintenance for ventilated patients, synthesized from multiple authoritative sources:
Propofol for Maintenance Sedation in Mechanically Ventilated Patients
Dosing
| Indication | Dose |
|---|---|
| ICU sedation (ventilated) | 25–75 mcg/kg/min via continuous infusion |
| Maintenance of GA (OR) | 100–200 mcg/kg/min |
| Maximum recommended dose (FDA, 2006) | ≤ 4 mg/kg/h (~67 mcg/kg/min) |
Titrate to a validated sedation scale (e.g., RASS or SAS) targeting the lightest level appropriate for the clinical situation.
Why Propofol is Preferred in the ICU
- Most common sedative agent for mechanically ventilated patients
- Equally efficacious as dexmedetomidine but less expensive
- More reliable at achieving deep sedation than dexmedetomidine
- Associated with shorter duration of mechanical ventilation and less delirium compared to benzodiazepines
- Continuous propofol with daily sedation interruption reduces ventilator days by an average of 5 days vs. benzodiazepines
- Short context-sensitive half-time allows rapid titration and faster awakening
Key Advantages Over Alternatives
| Feature | Propofol | Benzodiazepines | Dexmedetomidine |
|---|---|---|---|
| Depth of sedation | Deep, reliable | Deep | Light–moderate only |
| Duration of MV | Shorter | Longer | No benefit vs. propofol |
| Delirium risk | Lower | Higher | Similar to propofol |
| Amnesia | Yes | Yes | Unreliable |
| Hemodynamic stability | Can cause hypotension | Better | Bradycardia/hypotension |
| Cost | Moderate | Low | Higher |
Precautions & Monitoring
Hemodynamics:
- Can cause myocardial depression and worsen hypotension — use cautiously in hemodynamically unstable patients
Metabolic:
- Formulated in lipid emulsion (1.1 kcal/mL) — account for this in nutritional support calculations
- Monitor triglycerides periodically, especially with prolonged infusions or high doses
Propofol Infusion Syndrome (PRIS):
- Rare but potentially fatal (~50% mortality)
- Risk factors: high dose + prolonged duration (though short infusions have also caused it)
- Features: metabolic acidosis, hyperkalemia, hyperlipidemia, rhabdomyolysis, hepatomegaly, renal failure, ECG changes/arrhythmias, cardiac failure
- Pathophysiology: probable mitochondrial toxicity / impaired fatty acid oxidation
- Avoid prolonged high-dose infusions — keep to ≤4 mg/kg/h
Other side effects:
- Green discolouration of urine (benign, due to extrahepatic metabolites)
- Pain on injection (less relevant with central access in ICU)
Practical Notes
- Daily sedation interruption (awakening trials) is recommended — the evidence base for propofol largely derives from protocols using this strategy
- Propofol is generally avoided for prolonged sedation at high doses; if long-term deep sedation is required, reassess the need or consider alternatives
- In patients requiring neuromuscular blockade, propofol is appropriate (unlike dexmedetomidine or opioids, which do not reliably produce amnesia)
- In septic patients, both dexmedetomidine and propofol have been compared in major RCTs (MENDS2 trial) — propofol remains a first-line option
Sources: Barash Clinical Anesthesia 9e, p. 1479–1480; Morgan & Mikhail Clinical Anesthesiology 7e, p. 2538; Barash ICU chapter, p. 4858; Fishman's Pulmonary Diseases, p. 2677
This is a shared conversation. Sign in to Orris to start your own chat.